This course is now SOLD OUT. We are, however, planning to hold this course again later in the year, so if you would like to be added to the waiting list, please email firstname.lastname@example.org
Are you concerned about the latest developments regarding the assessment of endocrine disrupting (ED) properties? Wonder about the possible consequences for biocides and plant protection products?
Chemical Watch, in association with knoell Germany, is pleased to announce a brand new one-day training course on understanding the guidance for identifying endocrine disrupting chemicals in the biocides and crop protection area.
This course will provide you (risk assessors, regulatory managers and (eco-)toxicologists engaged with the assessment of biocidal and crop protection active substances/products) with comprehensive background information and in-depth insight into the new EU Endocrine Disruptor criteria, and the recent ECHA/EFSA Guidance.
The EU has finally agreed upon the long-awaited scientific criteria for the evaluation of substances with a potential for ‘endocrine disruption‘. The new ECHA/EFSA guidance for the identification of endocrine disruptors, published in June 2018 and applicable for plant protection products and biocides, requires a highly complex and challenging assessment for all substances. Particularly when dealing with such substances on a global scale, you may be facing substantial uncertainty regarding data requirements, testing and assessment strategies as well as impact outside the EU market.
In the field of biocides and plant protection products, the evaluating bodies are now obliged to also consider the ED properties of substances/products in any procedure that is still under the evaluation phase. As a consequence, from 07 June 2018 the evaluating competent authorities are assessing the potential ED properties of biocidal products, and since 10 November 2018 for plant protection products. Additionally for biocides, besides active substances also co-formulants contained in the biocidal products must be assessed. With a view to the ED assessment co-formulants represent a particular challenge in terms of available data package and data access, possibly requiring a revised assessment strategy.